74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Evotec AG
Closed
SectorFinance
5.93 -3.26
Overview
Share price change
24h
Min
5.74
Max
6.13
Income | 55M -40M |
|---|---|
Sales | 2.8M 185M |
Profit margin | -21.437 |
Employees | 5,007 |
EBITDA | 58M -45M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +111.22% upside |
Next Earnings | 17 Apr 2025 |
|---|
Market Cap | 1.1B |
|---|---|
Previous open | 9.19 |
Previous close | 5.93 |
News Sentiment
By Acuity
27%
73%
89 / 542 Finance
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Evotec AG Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Evotec AG Forecast
Price Target
By TipRanks
111.22% upside
12 Months Forecast
Average 12.8 EUR 111.22%
High 14 EUR
Low 11.6 EUR
Based on 2 Wall Street analysts offering 12 month price targets forEvotec AG - Dist in the last 3 months.
Sentiment
By Acuity
89 / 542 Finance
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Evotec AG
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
